Immune Checkpoint Targets for Immuno-Oncology Research
Immune checkpoints are highly interesting targets for cancer therapy because they play a key role in modulating the immune response. Cancer cells often develop strategies to prevent their own destruction by the host immune system by inhibiting the activation of immune checkpoints, which may allow cancer growth and metastasis. The concept of immune checkpoint inhibitor therapy is to use agents that facilitate the proper activation of immune checkpoints and the resulting destruction of cancer cells.
This eBook covers:
- Immune checkpoint targets by examining the tumor microenvironment, more specifically, the interaction between T cells and tumor cells.
- 2021 latest trends of immune checkpoint blockade in oncology research.
- In vivo functional grade antibody specifications for immuno-oncology application specific research and clinical purposes.
- Popular immune checkpoint biomarkers, including PD-1, CTLA-4, LAG-3, TIM-3, and more.
- Emerging immune checkpoint targets TIGIT, VISTA, B7-H3, BTLA.
- How Leinco Technologies’ assists preclinical researchers in their pursuit to cure cancer.
Gain access to the eBook by filling in the form below.